The global macular degeneration testing and therapeutics market is anticipated to expand at a CAGR of 3.28% amid the projected period to reach US$15.271 billion by 2030, from US$13.024 billion in 2025.
Macular degeneration testing and therapeutics are diagnostic methods and treatment approaches for the common eye condition, which affects the macula, the central part of the retina responsible for sharp, central vision. There are two main types of macular degeneration: dry (atrophic) and wet (neovascular or exudative). Tests include visual acuity tests, dilated eye exams, fluorescein angiography, optical coherence tomography (OCT), and genetic testing.
The market for macular degeneration testing and therapeutics includes diagnostic tools, pharmaceuticals, supplements, and medical devices designed to detect, monitor, and provide effective treatment options. Diagnostic tools include OCT machines, fundus cameras, fluorescein angiography systems, anti-VEGF drugs, supplements, intraocular implants, low vision aids, and genetic testing services. The market is driven by an aging population, advances in diagnostic imaging technology, and ongoing research into novel therapeutic approaches.
Expanding R&D endeavors and a rise in clinical trials characterized critical drivers of industry growth. R&D practices are anticipated to boost the macular degeneration testing and therapeutics industry. This incorporates expanding inventive therapeutic approaches, quality gene treatments, stem cell treatments, and combination treatments. Progressions in discovery and advancements in biomarkers empower early detection and personalized treatment. Progressed medication delivery frameworks are being created, involving novel formulations and sustained-release implants.
Additionally, Clinical trials are being started to guarantee the commercialization of new medicines and therapies. These endeavors are anticipated to lead to regulatory bodies' endorsements and the commercialization of new medications for macular degeneration. For instance, in November 2022, 4D Molecular Therapeutics, Inc., a clinical-stage biotechnology company specializing in focused on genetic medications, reported interim clinical discoveries from the Phase I/II trial of intravitreal 4D-150 for wet age-related macular degeneration (AMD).
The macular degeneration testing and therapeutics industry is expanding due to the increasing prevalence of age-related macular degeneration (AMD), a leading cause of vision impairment, particularly in the developing masses. Factors contributing to this advancement include the worldwide aging population, lifestyle habits such as poor diet causing malnutrition, an obese population, smoking, and drinking, strides in demonstrative technological advancements such as OCT, and extended awareness around the significance of eye wellbeing and screening programs.
The growing predominance of retinal disorders is contributing to industry development. For instance, research in August 2020 by the British Journal of Ophthalmology stated that AMD is the primary factor of visual incapacity and visual loss in Europe. Around 67 million individuals in Europe are affected by AMD, and this figure is expected to increase significantly to 15% by 2050 due to the expanding elderly population globally. These statistical data emphasize the rising number of people affected by retinal diseases, which particularly interfaces with the extended demand for macular degeneration treatment and in this way drives market expansion.
Market expansion in North America is driven by different components, like the increasing senior population and the predominance of age-related macular degeneration, in conjunction with the participation of key industry players and expanded R&D activities with the partnership of market players and academic research institutes. For instance, research published in Nature Medicine in August 2020 revealed that individuals with AMD who contract SARS-CoV-2 confront a higher risk of serious complications, including requiring supplemental oxygen or even fatal too.
The country's progressive healthcare framework, investigations for innovative technology, rising healthcare investment, government activities, awareness among patients, and academic research contribute to the macular degeneration testing and therapeutics industry expansion. Government initiatives and policies, as well as clinical trials, can offer assistance to identify and control AMD at an early stage. Generally, these components contribute to the advancement and commercialization of modern treatments in North America in the years ahead.
The American Macular Degeneration Foundation (AMDF) dispersed this data to alert both AMD patients and eye care experts about the potential risks involved. AMD is a leading cause of irreversible visual impairment and visual disability, contributing to industry growth. According to information from the Canadian Ophthalmological Society from February 2021, wet AMD positions among the essential causes of vision loss in people aged over 65. Moreover, information from the Conference Board of Canada expressed that the estimated cost of vision loss is projected to surge up to $30.3 billion by 2032 from $15.8 billion in the year 2007.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2025 | US$13.024 billion |
| Market Size Value in 2030 | US$15.271 billion |
| Growth Rate | CAGR of 3.28% from 2025 to 2030 |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2030 |
| Base Year | 2025 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segments Covered |
|
| Companies Covered |
|
| Regions Covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Customization Scope | Free report customization with purchase |
Global Macular Degeneration Testing and Therapeutics Market is segmented and analyzed as below: